• In late June 2026, Inspire Medical Systems, Inc. (NYSE: INSP) was removed from the large- and mid-cap Russell 1000 and Russell Midcap indices and added to a range of smaller-cap and style benchmarks, including the Russell 2000, Russell 2000 Growth and Value, Russell 2500 Value, and several Russell 3000-based value indices.
• This reshuffling shifts Inspire into the small‑cap and value‑oriented segments of the Russell family, potentially changing which index-linked investors hold the stock and how they size their positions.
• Next, we’ll examine how Inspire’s migration from the Russell 1000 to the Russell 2000 could influence its existing investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.

Inspire Medical Systems Investment Narrative Recap

To own Inspire Medical Systems today, you need to believe its implantable therapy for obstructive sleep apnea and the Inspire V rollout can justify the recent step down into small cap territory. The Russell index move itself does not change the underlying story, but it may add some near term trading noise just as Inspire works through slower growth, higher spending, and execution risk around its flagship system and SleepSync platform.

Among recent announcements, the SLEEP 2026 data around Inspire V and long term cardiovascular outcomes stand out. They speak directly to the main near term catalyst: proving that the newer system can sustain physician confidence, center productivity, and payer support despite rollout hiccups, while also showing enough real world benefit to defend the procedure against less invasive alternatives and possible reimbursement pressure.

Yet, despite the appeal of a more concentrated small cap story, investors should be aware that...

Inspire Medical Systems’ narrative projects $987.4 million revenue and $67.1 million earnings by 2029. This implies 2.6% yearly revenue growth and a $64.0 million earnings decrease from $131.1 million today.

Uncover how Inspire Medical Systems' forecasts yield a $52.17 fair value, a 14% upside to its current price.

Exploring Other Perspectives

The most bearish analysts were already assuming flat revenue around US$904.2 million and earnings near US$47.7 million, so the index downgrade plus rollout and reimbursement worries paint a far more cautious picture that you may want to compare with your own expectations.

Explore 9 other fair value estimates on Inspire Medical Systems - why the stock might be worth over 5x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Inspire Medical Systems research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Inspire Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Inspire Medical Systems' overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.